5/29/2012 1 IPEC-Americas General Update May 16, 2012 Membership Update With this weeks approval of Capsugel and Sensient, IPEC-Americas already has attracted 6 new members in 2012, 4 Full Members, 2 Associates Capsugel, Sensient Pharmaceutical Coating Systems Abbott Laboratories (a former member who has rejoined), and Air Liquide Industrial U.S. The new associates: NSF International and PSC Biotech, Inc.
17
Embed
IPEC-Americas General Update€¦ · Noven Pharmaceuticals (subsidiary of Hisamitsu), Mylan, Teva, Novartis, ... • Financial loss of $34,000 ... innovative drug formulations. A
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
5/29/2012
1
IPEC-Americas
General Update
May 16, 2012
Membership Update
With this weeks approval of Capsugel and Sensient, IPEC-Americas
already has attracted 6 new members in 2012,
4 Full Members,
2 Associates
Capsugel,
Sensient Pharmaceutical Coating Systems
Abbott Laboratories (a former member who has rejoined), and
Air Liquide Industrial U.S.
The new associates: NSF International and PSC Biotech, Inc.
5/29/2012
2
Membership Update
During ExcipientFest 2012, contact information was received from 10 more full member
candidates and 2 potential associate members:
ACG North America LLC
AstraZeneca
Bayer Healthcare
Bristol-Myers Squibb
DFE Pharma
Grain Processing Corporation
Nutrilite Health Institute (Amway)
Patheon
Sensient Pharmaceutical Coating Systems
Tris Pharma
The potential associates include a professor of pharmaceutics from the University of Puerto
Rico, Evone Ghaly, and an industrial freight company, C&F Worldwide Agency Corp.
Membership Update
• Initial membership materials have been sent to most contacts and the rest will be sent this week.
• Regarding other potential candidates, follow up with them also is underway to attract companies such as:
Glenmark Generics,
Corn Products,
Noven Pharmaceuticals (subsidiary of Hisamitsu),
Mylan,
Teva,
Novartis,
Endo Pharmaceuticals,
Cephalon,
PAR Pharmaceutival, and
Lonza.
Names of possible contacts in those companies are invited and needed.
5/29/2012
3
Upcoming Booths/Shows
• July 15 – 18 CRS (Controlled Release
Society) Poster Session for NESEP & Marketing
Opportunity – Quebec
• Oct. 14 – 17 AAPS – Chicago
• Booth - Foundation awards & dinner
Current Income – Cash Flow
Report
• Member dues – TOTAL TO DATE: $661,968
– 41 of 47 full members have paid
– Dues from the other six full members are expected
– 19 of 27 associates have paid
– $41,282 from 5 new members
• Other income • Multiview – newsletter advertising
• IPEC training – 2011 webinars
• GMP, Interest,
5/29/2012
4
Current Income – Cash Flow
Report
•Legislative Contributions $103,129
•$20K moved from 2011 to 2012 (included in figure above)
•2012 To date: Spent $65,431,73
•Currently have $37,286 expect addtl. 4K
•If all expected contributions are received
we can fund leg. initiative UP TO August
ICH Q3D Workshop
Bethesda, MD April 4-5, 2012
ICH Q3D Workshop Increases Awareness of
Current Elemental Impurities Issues
On April 4-5, representatives of 39 pharmaceutical companies,
ingredient suppliers, the U.S. Food and Drug Administration, The
United States Pharmacopeia, officials of the three sponsoring
organizations, e.g., IPEC-Americas, SOCMA, and the Consumer
Health Care Products Association all came together with
pharmaceutical industry press personnel for a one and a half day
workshop at the Marriott Hotel in North Bethesda, MD.
5/29/2012
5
ICH Q3D Workshop
Bethesda, MD April 4-5, 2012
ICH Q3D Workshop
Bethesda, MD April 4-5, 2012
• Speakers 6
• Press 4
• FDA/Govt/USP 5
• Attendance 71 (41 Member / 15 Non-Member)
• Financial loss of $34,000 ($11,000-IPEC-Americas)
Among the companies represented were excipient and API suppliers, non-prescription drug manufacturers, generic pharmaceutical product suppliers and companies that develop and gain approval to market innovative drug formulations.
A report summarizing the discussions and outcomes from the workshop has been forwarded to the ICH EWG for their consideration.
Key themes from the breakout sessions included:
• Potential misinterpretations regarding testing and risk assessments
• Recommendations on clarification of risk assessments and testing
• Request for additional detail about types of metals likely to be present
• Bioavilability and exposure to the patient
• Timelines and implementation
• Reformulation of existing products
5/29/2012
6
ICH Q3D Workshop
Bethesda, MD April 4-5, 2012
ICH Q3D Workshop
• ICH Q3D Workshop Results ICH Q3D Workshop - April 4-5, 2012
Income Total participants 71
Paid Registrations
Speakers 6 comp
Press 4 comp
Member 41 $600 early bird or $650
Non member 15 $900 early bird or $950
FDA/GOVT/USP 5 $350
71 $ 40,715.00
Expenses
Bethesda North Marriott Hotel $ 50,087.21
Legal fees $ 21,412.50
Related travel and hotel costs - STAFF $ 1,220.60
Printing (program, signage) $ 312.76
Credit Card processing fees $ 1,796.97
Income/Expense Results $ 74,830.04
$ (34,115.04)
5/29/2012
7
ICH Q3D Workshop
•CHPA & SOCMA – Owe IPEC-A $10,000 each
•IPEC-Americas total loss: $14,115
•All agree value for price paid worthwhile
investment.
ExipientFest Americas 2012
5/29/2012
8
ExipientFest Americas 2012
ExipientFest Americas 2012
5/29/2012
9
ExipientFest Americas 2012
5/29/2012
10
Top read articles and links: 1. USP Workshop on Supply Chain Integrity Will Discuss Good Distribution
Practices (wrong link) 2. Recent China Gelatin Capsule Adulteration Case Appears Resolved 3. FDA Expands Global Initiative 4. USP Update on Elemental Impurities (link to hot topics) 5. Certification to the Upcoming Excipient GMP American National Standard
5/29/2012
11
Strategic Planning 2013
• January 14 – 17, 2013
• Marriott Hilton Head
• Hilton Head, SC
• Facilitator: Chris Moreton
• Committee Chair strategic planning
meeting ½ day
Office Space
• Current lease expires December 2012
• Space available on 1st floor
• $39/sq. ft
• 2567 sq. ft
• Turn-key improvements - if 5 year lease
5/29/2012
12
Alan Mercill honored for years of IPEC service at the Executive Committee dinner Monday night, at
Morton’s Steakhouse
5/29/2012
13
Alan Mercill honored for years of IPEC service at the
Executive Committee dinner Monday night, at Morton’s Steakhouse
Alan Mercill honored for years of IPEC service at the Executive Committee dinner Monday night, at
Morton’s Steakhouse
5/29/2012
14
IPEA Update
• Financial • Current balance: $8,488
• Accounts Receivable: $14,500
• Accounts Payable : $5,500 (2 x Certification board meetings)
• May payroll ($4,200) rent share ($1,166) paid to IPEC
• Business 2012 • 2 Surveillance audits-January + 1 being planned
• 5 Audit Reports sold: 3 Certification /2 standard audit
• IPEA 2012 Budget Projection: 11 reports
IPEA Update
• Unplanned/Not budgeted
Expenses • Trademark affidavit fee: $13,680 – was paid in 3 installments
• IPEA 2012 Budget Projection: $5,000
Income • 1 Gap Assessment (Europe) TBD
• 1 Auditor Training session for EXCiPACT
• 3 Audits (standard)
• October Auditing workshop
Opportunities 1. Rx360: Accepted the IPEA application and asked for an agreement and cost estimate
• Agreement prevents IPEA from certifying any company we audit
• Lack of information impedes development of cost estimate
2. NSF: agreement provides nothing for IPEA. Will submit to NSF an outline for a mutually beneficial agreement.
3. ANSI Accreditation scope addition: Good Distribution Practices.
5/29/2012
15
IPEC Foundation
• Updated website complete
• Application season open – 2 received
• Meeting with AAPS –April 30 Possible 5 K
partnership with AAPS and/or
ExcipientFest to raise money for awards
• Gala Dinner for 2013?
• AAPS actively promoting Shangraw &
Grad Student Awards
IPEC Legislative Update:
Capitol Hill Campaign
Presented By Buchanan Ingersoll & Rooney, PC
May 14, 2012
5/29/2012
16
Legislative Update: FDA User-Fee Legislation
Latest IPEC Hill Engagement
House E&C Health Subcommittee:
– House E&C Subcommittee on Health Hearing- “Reauthorization of PDUFA: What It Means for Jobs, Innovation, and Patients” (Feb. 1, 2012): FDA Commissioner appeared before the subcommittee. Remarks in the form of a letter to the subcommittee chair and ranking member submitted.
– Chairman Joe Pitts Meetings- (April 12 &26) Meetings with Monica Volente, Legislative Director for Chairman Pitts and Clay Alspach, Legislative Counsel for the Health Subcommittee to discuss Supply Chain Security issues in House User-Fee Bill.
– Chairman Pitts Fundraiser- (April 16) Had follow-up conversation with Chairman Pitts specifically about IPEC suggestions to Senate HELP “discussion draft” and prospects for House bill.
Senate HELP Committee: – HELP Committee “Discussion Draft”- (March 30) IPEC submitted written
comments with several suggested changes.
– HELP Committee Staff Meeting- (May 3) Meeting with Kathleen Laird (Committee/Harkin), Grace Stuntz (Committee/Enzi) and Elizabeth Jungman (Committee Counsel) to discuss two changes to “redlined” draft.
Legislative Update: Capitol Hill Campaign
Current Situation
Both House Energy and Commerce Committee and Senate HELP Committee have passes their version of FDA User-Fee legislation.
– House Energy & Commerce Health subcommittee passed their bill by voice-vote on May 8th and the full E&C Committee passed the legislation (46-0) on May 10th after a subcommittee “mark-up” false start in April.
– Senate HELP Committee approved their bill on April 25th by voice vote.
User-Fee Timeline
– House Majority Leader Eric Cantor indicated that the full House will consider User-Fee legislation by the end of May.
– Senate HELP staff (as of this morning) thought Senate would take up bill in May,
but are in discussion with Majority Leader Harry Reid late today or tomorrow.
Final Passage
– House Energy & Commerce Chairman Fred Upton has said he hopes that a final
bill will be sent to the President for his signature by July 4.
5/29/2012
17
Legislative Update: FDA User-Fee Legislation
Final Notes:
– The Senate HELP Committee-passed version is far better in terms of those
issues advocated by IPEC. The House version touches on some of the issues
IPEC finds important, but is very heavily dependent on FDA drafting the correct
regulations.
– The House draft bill has no real detail on third-party auditing (just a brief mention
in 809).
– Excipients are not specifically mentioned and so our concern is that, if the House
version were passed into law (highly unlikely), it is not expressly clear that
excipients are covered.
– Chairman Pitts (House Health Subcommittee) promised to work in conference to
support IPEC’s Senate position.
– Staff for Chairman Tom Harkin and Ranking Member Mike Enzi (Senate HELP
Committee) felt comfortable that IPEC’s suggested changes from May 3rd would
be part of Senate Floor activity.
Upcoming Meetings
• Important Industry Meetings June 5 – 7 PDG Meeting – Yokohama, Japan
• June 13-14 — NIPTE RESEARCH CONFERENCE , FDA Conference Facilities White Oak, Silver Spring, MD Register at www.nipte.org. July 15-18 — CRS 39th Annual Meeting, Smart Materials - From Innovation to Translation Centre des Congres de Quebec, Quebec City, Canada To register and learn more go to: http://www.controlledreleasesociety.org Sept. 24-27 — IPEC-Americas Committee/Working Group Meetings, see the schedule on IPEC-Americas website at: http://ipecamericas.org/content/2010-ipec-americas-calendar-events. Oct. 23-25 — IPEA GMP Auditing Workshop, Houston, Texas http://ipeainc.com/auditing-workshop
• Nov. 26-27 – 2nd Annual European Conference on Excipients, Berlin, Germany •
Nov. 28-29 — ExcipientFest China – www.excipientfest.asia